Learn more about Tarceva
Tarceva is a potent oral EGFR tyrosine kinase inhibitor proven to significantly prolong survival in second-line NSCLC. Find out how Tarceva works as well as its established safety profile. Approval and labeling information are available for download.
Learn more
Survival benefits in second-line NSCLC patients
Tarceva is available in three strengths - 150 mg, 100 mg and 25 mg - to allow for dose reduction if necessary. Tarceva provides significant survival benefits, symptom control and disease control.
Learn more
Physician resources
Download physician materials on Tarceva that can be printed or saved to your computer. Lecture slides are also available for your use. Find out about upcoming congresses around the world.
Learn more
Tarceva.com
This site is only intended for use by healthcare professionals outside of the US. If you are a US resident, please visit www.tarceva.com.
Patient support
Download patient-oriented brochures on Tarceva, as well as the Tarceva package leaflet to help your patients learn more about Tarceva, how to take it and what to expect during treatment. Helpful links are provided for cancer foundations and support groups around the world.
Learn more
- Disclaimer: Tarceva.net is a comprehensive resource for healthcare professionals outside the US. If you are a US resident please visit www.Tarceva.com. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
- © 2009 F. Hoffmann-La Roche Ltd.